Blue Jet Healthcare Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Blue Jet Healthcare Ltd filed with BSE on 29 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Blue Jet Healthcare reported Q4 FY26 revenue of Rs 235 crore, up 22% quarter-over-quarter but down 31% year-over-year, while full-year FY26 revenue of Rs 947 crore declined 8% versus FY25 as the PI/API segment was hit by customer destocking. The contrast media segment grew 23% for the full year on strong customer offtake, partly offsetting weakness in PI/API and artificial sweeteners. Management described progress on the Vizag greenfield project, the Mahad backward integration, and a new Hyderabad R&D center, and said it expects improved visibility heading into FY27.
Numbers mentioned
Revenue: Rs 235 crores (Q4 FY26)
p. 5
“Q4, we reported a revenue of INR235 crores, an increase of 22% on a quarter-over-quarter basis and a decline of 31% year-over-year basis.”
Ganesh Karuppannan, page 5 of the filed PDF · View the filing
Revenue from operations: Rs 947 crores (FY26)
p. 5
“Our reported revenue from operations in FY26 of INR947 crores is a decline of 8% compared to FY25.”
Ganesh Karuppannan, page 5 of the filed PDF · View the filing
Contrast media revenue: Rs 193 crores (Q4 FY26)
p. 5
“Q4, we reported a revenue of INR193 crores, an increase of 55% on a quarter-over-quarter basis and an increase of 91% year-over-year basis.”
Ganesh Karuppannan, page 5 of the filed PDF · View the filing
Contrast media revenue: Rs 495 crores (FY26)
p. 5
“Our reported revenue from operations in FY26 full year of INR495 crores is an increase of 23% compared to FY25.”
Ganesh Karuppannan, page 5 of the filed PDF · View the filing
PI/API revenue: Rs 298 crores (FY26)
p. 5
“Our reported revenue from operations in this category for FY26 full year of INR298 crores is a decline of 35% compared to FY25.”
Ganesh Karuppannan, page 5 of the filed PDF · View the filing
Artificial sweetener revenue: Rs 131 crores (FY26)
p. 6
“Our reported revenue from operations in FY26 of INR131 crores is a decline of 2% compared to FY25.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Gross margin: 54% (FY26)
p. 6
“For the full year FY26, our reported gross margin is at 54% compared to 55% in FY25.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
EBITDA margin: 31% (FY26)
p. 6
“Reported EBITDA for FY26 is 31% against 37% for FY25.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Other income: Rs 69 crores (FY26)
p. 6
“Reported other income for FY26 is at INR69 crores compared to INR46 crores for FY25.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Profit after tax margin: 26% (FY26)
p. 6
“Reported profit after tax continue to be healthy at 26% for FY26 against 30% in FY25.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Capital work in progress: Rs 301 crores (as on March 2026)
p. 6
“The total CWIP as on March '26 stood at INR301 crores.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Liquid financial assets: Rs 400 crores (FY26)
p. 6
“We ended FY26 with liquid financial assets of INR400 crores as against INR306 crores in FY25.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Cash flow from operating activities: Rs 334 crores (FY26)
p. 6
“Cash flow from operating activities stood at INR334 crores.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Vizag capex — approximately INR1,000 crores over 3 years · approximately 3 years
stated firmly by VK Singh
p. 4
“The total capex that we envisage for the Vizag project is approximately INR1,000 crores over a period of approximately 3 years.”
VK Singh, page 4 of the filed PDF · View the filing
Hyderabad R&D center investment — approximately INR40 crores
stated firmly by VK Singh
p. 4
“Our upcoming R&D center in Hyderabad with a planned investment of about INR40 crores will focus on newer chemistry platforms including peptide-related intermediates, GLP-1 linked opportunities, biocatalysts and, of course, a faster turnaround of CDMO development programs.”
VK Singh, page 4 of the filed PDF · View the filing
Contrast media new product launches — 3 to 4 new product launches · current year
stated conditionally by VK Singh
p. 5
“In the contrast media segment, we expect 3 to 4 new product launches during the current year, further expanding our participation across advanced intermediates within this space.”
VK Singh, page 5 of the filed PDF · View the filing
PI/CDMO RFP commercialization — 2 opportunities moving into commercialization · current year
stated conditionally by VK Singh
p. 5
“Encouragingly, we believe that 2 of these opportunities are expected to move into the commercialization phase during the current year.”
VK Singh, page 5 of the filed PDF · View the filing
FY27 capex — approximately INR400 crores · FY27
stated firmly by Ganesh Karuppannan
p. 6
“We propose to spend approximately INR400 crores in FY27 towards Vizag greenfield, completion of Mahad and other additions in Ambernath.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Mahad facility commissioning — commencement of production · H2 FY27
stated firmly by Ganesh Karuppannan
p. 6
“Mahad facility is in the final stages of completion and is expected to start commencement of production in H2 FY27.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Contrast media growth — double-digit growth · FY27
stated conditionally by Ganesh Karuppannan
p. 9
“we do expect 1 or 2 validations and 1 commercial launch, which should actually like ensure that we will actually get into a sort of double-digit growth.”
Ganesh Karuppannan, page 9 of the filed PDF · View the filing
Contrast media annual forecast growth — mid-single digit growth · FY27
stated conditionally by Ganesh Karuppannan
p. 5
“Annual forecast from the customer has a mid-single digit growth for FY27.”
Ganesh Karuppannan, page 5 of the filed PDF · View the filing
Vizag capacity timeline — blocks online · 24 to 30 months
stated firmly by VK Singh
p. 8
“But then, as you know, that Vizag is completely greenfield. And we envisage 24 to 30 months for that capacity to get online.”
VK Singh, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said inventory destocking has happened and orders are now in hand, with new product launches expected over time.
Answered by VK Singh
Asked by Sanjesh: What gives confidence on PI segment crossing FY25 peak and is it order-confirmed?
p. 7
“So we are quite confident that in the PI segment, we are getting to a very good set of numbers in the coming year.”
VK Singh, page 7 of the filed PDF · View the filing
Yes, lab supplies have begun to some innovators and large peptide CDMOs.
Answered by VK Singh
Asked by Sanjesh: Have lab or pilot supplies started for peptide building blocks?
p. 8
“Yes. We have started lab supplies to some innovators and we have also started some lab supplies to some very large peptide CDMOs.”
VK Singh, page 8 of the filed PDF · View the filing
Management attributed it to customer offtake patterns rather than uniform market growth, cautioning against reading too much into quarterly numbers.
Answered by Ganesh Karuppannan
Asked by Pritesh Chheda: What explains the 22% quarter-on-quarter growth in contrast media?
p. 9
“So in this particular CDMO activity, one should not look at monthly or a quarterly. I think as long as we get that annual number right, I think that would be a better way to forecast.”
Ganesh Karuppannan, page 9 of the filed PDF · View the filing
Management said it is too early to comment and will have better visibility after Q1 FY27.
Answered by Ganesh Karuppannan
Asked by Samitinjoy Basak: What margin outlook is expected for FY27 given geopolitical and logistics pressures?
p. 11
“So Q1 would be the -- could actually give you a good representation of how the cost structures have evolved and how the margins are.”
Ganesh Karuppannan, page 11 of the filed PDF · View the filing
Management said there is no current supply disruption and does not foresee any in coming quarters.
Answered by Shiven Arora
Asked by Ritika Agarwal: Is there any risk from a customer's warning letter regarding a formulation plant?
p. 12
“From my side, I think it's business as usual in this particular segment. And we don't see -- foresee any disruption in the coming quarters also.”
Shiven Arora, page 12 of the filed PDF · View the filing
Management said margins would be comparable or better but flagged potential for faster price erosion in that segment.
Answered by VK Singh
Asked by Dheeraj Kumar Reddy: Will initial peptide molecules be margin accretive?
p. 14
“The margins will be very good, in line or better than what we have. But then you must understand that as compared to the other segments, there could be faster, higher price erosion in this segment.”
VK Singh, page 14 of the filed PDF · View the filing
Management said the company is far from peak utilization due to ongoing capacity creation and debottlenecking.
Answered by Shiven Arora
Asked by Ravi Purohit: Is current contrast media revenue near peak capacity?
p. 14
“I think we are -- as far as contrast media is concerned, we are far away from the peak utilization levels because of the ongoing works from the company side in terms of capacity creation, debottlenecking across products.”
Shiven Arora, page 14 of the filed PDF · View the filing
Management confirmed destocking has run its course and shipments are resuming.
Answered by VK Singh
Asked by Keshav Bagdi: Is the worst behind for the pharma intermediates/API segment?
p. 16
“But then all that we will say is that whatever destocking had to happen has happened, and the plant has been now running to optimum capacity and the shipments have started rolling out.”
VK Singh, page 16 of the filed PDF · View the filing
Management said the situation is dynamic and the company is accelerating capex while remaining debt-free.
Answered by Ganesh Karuppannan
Asked by Hitansh Shah: Are there plans to raise funds for the Vizag investment?
p. 17
“I think the situation is dynamic right now. I think we'll be able to update you in the coming quarters.”
Ganesh Karuppannan, page 17 of the filed PDF · View the filing
Risks flagged
Rupee/raw material price volatility from geopolitical events including the Iran war
p. 6
“In FY26, rupee depreciation improved realization of exports and negated raw material price increase, which happened in the last month of the financial year due to Iran war.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Rising freight and logistics costs post March 2026
p. 6
“Freight cost post March '26 have increased. While the impact is not felt in FY26, logistics costs in FY27 will have to be evaluated.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Pricing pressure on artificial sweeteners from imports
p. 6
“This category faced pricing pressure from imports and we will remain opportunistic.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Potential price erosion in peptide segment as competition increases
p. 14
“But then you must understand that as compared to the other segments, there could be faster, higher price erosion in this segment.”
VK Singh, page 14 of the filed PDF · View the filing
Customer warning letter with possible escalation to import alert
p. 12
“So which means that the commercial impact should not be there till the time there's an import alert.”
VK Singh, page 12 of the filed PDF · View the filing
Impact of crude oil price rise on chemicals and logistics costs
p. 10
“See, you know the impact of crude oil price, which has actually impacted most of the chemicals, logistics cost, and there is also going to be a domino effect, okay?”
Ganesh Karuppannan, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.